MA-QUANTORI
Quantori, a leading data science and digital transformation services company for the life sciences and healthcare sectors, today announced the appointment of Sean Murphy as Vice President of Client Services, effective immediately. Sean will oversee Quantori’s global network of IT professionals providing world-class software engineering and data analytics services to top biopharma and healthcare companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210720005589/en/
“Sean has a strong track record of leading cross-functional teams to deliver innovative digital IT solutions that support a seamless digital transformation experience,” said Richard Golob, CEO of Quantori. “As we enter our next phase of growth, we are thrilled to welcome Sean aboard to ensure delivery of cost-effective, high-quality data science and software engineering services.”
Sean has held various leadership positions at AstraZeneca and Thermo Fisher Scientific, where he focused primarily on R&D IT and Cloud and Digital Transformations. At AstraZeneca, Sean designed, developed, and led the Application Lifecycle Services organization, a world-class software engineering team that delivers quality products and services throughout AstraZeneca. He also was instrumental in establishing captive offshore development centers for AstraZeneca.
Most recently, Sean served as Vice President at General Electric, where he was the Technology Leader for the business and digital transformation of corporate systems. He focused predominately on the implementation of the enterprise SaaS solution Workday across all General Electric businesses.
Sean received his B.S. degree in Business Administration from the University of New Hampshire and his M.Sc. degree in Management with a specialization in Biopharmaceutical Leadership from Emmanuel College. He currently serves as a board member of the United Nations Association of Greater Boston and has served as a board member of the Society for Information Management of Boston and Newton Girls Soccer.
“I’m excited to join the highly impressive Quantori leadership team to help deliver nextgen data science and software solutions that provide immediate value for our clients,” according to Sean. “While at AstraZeneca, I had the pleasure of working with some of the professionals who are now Quantori’s leaders. They were the only service providers who truly understood the drug development process and the scientific problems we were trying to solve. I was so impressed with their performance and ability to deliver that I wanted to join the team!”
Quantori’s executive leadership boasts a rich history in the life sciences and healthcare IT industry. CEO Richard Golob, Chief Scientific Officer Yuriy Gankin, Ph.D., and Chief Technology Officer Vitaliy Aronov have successfully joined forces for more than two decades to deliver award-winning software engineering and data analytics services to top pharmaceutical companies and research organizations around the globe. They previously cofounded GGA Software Services, which was acquired by EPAM Systems in 2014. Golob built EPAM’s Life Sciences Business Unit into the fastest growing unit at the company.
“What we’ve experienced over the past year is that our clients require a versatile digital IT services provider that understands their needs for scalability and flexibility and has deep domain and data science knowledge, and Quantori checks all these boxes,” said Yuriy Gankin, Chief Scientific Officer at Quantori. “Sean’s background in helping organizations navigate the digital revolution will be invaluable in helping us fulfill our mission to empower our clients to achieve their strategic business goals.”
Quantori’s global headquarters are located in Cambridge, Massachusetts, with additional offices in London, U.K., St. Petersburg, Russia, and Tbilisi, Georgia. The company serves leading research institutions and biopharma organizations, including Bruker, The Jackson Laboratory, Perkin Elmer, and Takeda. Quantori’s team is currently more than 400 professionals, and the company is actively seeking qualified experts globally to keep pace with its rapid growth. For more information, please visit www.quantori.com or email info@quantori.com .
“The robust software engineering, scientific informatics and data science capabilities that Quantori offers have enabled us to achieve our IT strategy by harnessing the power of innovative digital technologies,” said Scott Thomas, Vice President of Information Technology for the LGC Genomics Division. “The COVID-19 pandemic has significantly increased demand for genomic analysis, and Quantori’s digital solutions have helped optimize our operations to meet the demand for these mission-critical applications.”
About Quantori
Quantori is transforming life sciences and healthcare with the power of digital IT. The company develops bespoke IT and data science solutions for accelerating research and drug discovery and improving healthcare delivery. Quantori combines data engineering and advanced analytics with scientific knowledge management and best-in-class software engineering to help life science and healthcare companies successfully achieve their digital transformations with greater speed and agility. Learn more at www.quantori.com and connect on social media @Twitter , @LinkedIn , and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005589/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom